## Rare Pediatric Diseases are common and demand mechanism discovery to understand the disease process

Voice of the Patient – NIH October 2019

Mustafa Khokha, MD Director, Pediatric Genomics Discovery Program Associate Professor, Yale University School of Medicine



#### Yale Medicine


Yale NewHaven Health Yale New Haven Hospital



#### Yale school of medicine

#### Impact of Rare disorders/Birth Defects

- Combined, rare disorders are surprisingly common
  - 2% of population
  - 10% of hospital discharges
- Birth defects #1 cause of infant mortality in the US




NewHaven

Yale New Haver

Health

#### Impact of Rare disorders/Birth Defects



Yale NewHaven

Yale New Have

Health

Yale school of medicine

#### Impact of Birth Defects

- In each age category
  - Birth defects are top 3 cause of death
  - In first decade of life more children die due to birth defects than any other cause
  - Structural birth defects
  - Rare disorders life-threatening
- Genetic basis generally unknown
- Rare disease/Birth Defects individually are very rare – COMBINED – highly common and the major cause of childhood death

| Rank                                       | <1                                      | 1-4                              | 5-9  |  |  |  |
|--|---|----------------------------------|--|--|--|--|
| 1  | Congenital<br>Anomalies<br>4,580        | Unintentional<br>Injury<br>1,267 | Unintentional<br>Injury<br>718               |  |  |  |
| 2  | Short<br>Gestation<br>3,749             | Congenital<br>Anomalies<br>424   | Malignant<br>Neoplasms<br>418                |  |  |  |
| 3  | Maternal<br>Pregnancy<br>Comp.<br>1,432 | Malignant<br>Neoplasms<br>325    | Congenital<br>Anomalies<br>188               |  |  |  |
| 4  | SIDS<br>1,363                           | Homicide<br>303                  | Homicide<br>154                              |  |  |  |
| 5  | Unintentional<br>Injury<br>1,317        | Heart<br>Disease<br>127          | Heart<br>Disease<br>75                       |  |  |  |
| 6<br>Placenta<br>Cord.<br>Membranes<br>843 |   | Influenza &<br>Pneumonia<br>104  | Influenza &<br>Pneumonia<br>62               |  |  |  |
| 7  | Bacterial<br>Sepsis<br>592              | Cerebro-<br>vascular<br>66       | Chronic Low.<br>Respiratory<br>Disease<br>59 |  |  |  |
| 8  | Circulatory<br>System<br>Disease<br>449 | Septicemia<br>48                 | Cerebro-<br>vascular<br>41                   |  |  |  |
| 9  | Respiratory<br>Distress<br>440          | Benign<br>Neoplasms<br>44        | Septicemia<br>33                             |  |  |  |
| 10   | Neonatal<br>Hemorrhage<br>379           | Perinatal<br>Period<br>42        | Benign<br>Neoplasms<br>31                    |  |  |  |
|  |   |                                  |  |  |  |  |



#### Why study rare disorders?

- So why study?
  - Rare disorder Impacts a single family, handful of families
  - Combined they are very common 1 in 10 Americans
- Huge impact on child health
- physicians struggle to make correct diagnosis, patients respond unpredictably to therapy
  - Families frustrated, isolated, desperate
  - Why did this happen? What is going on?
  - Will this happen to my next child?
- OPPORTUNITY



#### Extraordinary Opportunity

- Likely genetic basis for these disorders
  - Rarity
  - Locus heterogeneity
  - Serious illness (life-threating disease)
  - Standard genetic strategies for gene discovery are limited
- DNA sequencing
  - Inexpensive
  - Identify candidate genes efficiently
  - Transforms our insight into disease pathogenesis

Combine to make pedigrees or multiple allele discovery unlikely



#### Sequencing is not enough

- Novel Gene discovery ?pathogenesis
- 20,000 genes in our genome
  - Established causes of disease (25%)
  - No previous association with disease (75%)
- Understanding how the gene causes disease powerful
  - Understand gene function understand disease process
  - Creates opportunities to tailor diagnostics and therapy based on genotype
  - Predict complications, outcome



#### Three remarkable opportunities - Today

- Opportunity to convert descriptive diagnosis to molecular diagnosis
- Opportunity to discover new biology
- Opportunity to return these results to families desperate for answers



## From patients, to fundamental science, to answers for families



#### The heterotaxy gene GALNT11 glycosylates Notch to orchestrate cilia type and laterality

Marko T. Boskovski<sup>1</sup>\*†, Shiaulou Yuan<sup>1</sup>\*, Nis Borbye Pedersen<sup>2</sup>, Christoffer Knak Goth<sup>2</sup>, Svetlana Makova<sup>1</sup>, Henrik Clausen<sup>2</sup>, Martina Brueckner<sup>1</sup> & Mustafa K. Khokha<sup>1</sup>

CellPres

RAPGEF5 Regulates Nuclear Translocation of  $\beta$ -Catenin

John N. Griffin,<sup>1,2</sup> Florencia del Viso,<sup>1</sup> Anna R. Duncan,<sup>1</sup> Andrew Robson,<sup>1</sup> Woong Hwang,<sup>1</sup> Saurabh Kulkarni,<sup>1</sup> Karen, I. Liu <sup>2</sup> and Mustafa K. Khokha<sup>1,3,\*</sup>

Developmental Cell Article

#### WDR5 Stabilizes Actin Architecture to Promote Multiciliated Cell Formation

Saurabh S. Kulkarni,<sup>1,2,3</sup> John N. Griffin,<sup>1,2,3</sup> Priya P. Date,<sup>1,2,3</sup> Karel F. Liem, Jr.,<sup>2</sup> and Mustafa K. Khokha<sup>1,2,3,4,\*</sup>

CellPress

Developmental Cell Article


doi:10.1038/nature12723

Developmental Cell

#### Congenital Heart Disease Genetics Uncovers Context-Dependent Organization and Function of Nucleoporins at Cilia

Yale school of medicine

Florencia del Viso,<sup>1,4</sup> Fang Huang,<sup>2,3,4</sup> Jordan Myers,<sup>2</sup> Madeleine Chalfant,<sup>2</sup> Yongdeng Zhang,<sup>2</sup> Nooreen Reza,<sup>1</sup> Joerg Bewersdorf,<sup>2</sup> C. Patrick Lusk,<sup>2,\*</sup> and Mustafa K. Khokha<sup>1,5,\*</sup>




Yale Medicine



**Cell**<sup>2</sup>ress

#### Patient driven discovery -> Future therapy

- <u>Colorectal Cancer</u>
- 3rd most common
- 9.4 million people in 2015
- 65% survival
- 832,000 deaths
- <u>Colorectal Cancer + Wnt Pathway</u>
- 90% of Colon cancer
- APC, Axin1/2,  $\beta$ -catenin
- Stabilize β-catenin
- Blocking mechanism β-catenin nuclear entry – <u>no one knows how</u>






#### Return results to patients

- Rare disorders poor understanding of pathophysiology, parents become the experts frustration, desperation
- Birth defects diagnosis is descriptive not molecular
- DNA Sequencing
  - Why did this happen? What is going on?
    - Candidate genes may explain disease process
  - Will this happen to my next child?
    - Evaluate potential risk to next child based on the genetics
- Traditionally Basic science offers therapies in the future
- Sequencing Era basic science can immediately provide answers



#### Clinical – Basic Science Infrastructure




Health Yale New Haven

Yale school of medicine

Yale Medicine



#### Pediatric Genomics Discovery Program



Yale school of medicine

Yale Medicine



SLIDE 12



- Extraordinary opportunity for rare disease/birth defects research
- To capitalize on this opportunity: Must address a number of problems



#### **PROBLEM – Impact Underappreciated**

- Impact of Birth Defects/Rare Disease on children is massive
- **Underappreciated** by the general public
- Resources not proportional to the impact
- Why?
  - Premature infant in the palm of one's hand
  - Unmistakable look of child with cancer
  - No heart tugging image of birth defect child "cripple"
- Solution Public education of the impact
  - Write in lay press
  - Alert our legislators, policy makers



#### PROBLEM – Rare diseases are rare

- So why study?
  - Impacts a single family, handful of families
  - Collectively common
- Rare disorders/birth defects
  - Families/Physicians desperate for answers
  - Unsatisfying descriptive diagnoses not molecular
- SOLUTION change the research metric. Research to help patients today return of results (even research results) to patients
- SOLUTION Emphasize Patient driven gene discovery.
  - Patient as powerful motivator to "new" biology
  - Patient phenotype as powerful guide for pathogenesis discovery
  - Connect clinicians and basic scientists.
- To realize this potential study patient derived genes need disease models



#### Convert Clinical/Candidate Gene -> Basic Science

- Models for human disease
- Throughput for DNA sequencing is FAST...
- Create disease Models
  - Mouse models throughput and cost
  - Non-mammalian models
  - Xenopus F0 CRISPR Gene to phenotype in 5 days
    - As similar to human without sacrifice on throughput lungs, limbs
    - Annotated genome, Model Organism Database: Xenbase
    - National Xenopus Resource animal stock center
  - Patient derived cells animal models offer 3D architecture to model human disease. Test specific hypotheses in patient cells.



#### Convert Clinical/Candidate Gene -> Basic Science

- Fund studies of patients with rare disorders
  - Fund proposals to recruit patients and sequence GM KidsFirst
  - Fund proposals to study candidate genes from patient driven gene discovery – basic science of novel genes
- To capitalize on <u>return to patient</u> create basic science-clinical infrastructure
- PROBLEM#1: Diverse expertise: patients are seen by clinicians, exome sequencing requires bioinformatics, modeling of human disease and mechanism discovery requires basic scientists
- PROBLEM#2: Hypothesis generating not hypothesis driven
  - Grant proposal recruit patients (broad), find candidate genes (unknown until patients recruited), discover cool biology that impacts patients (unknown until sequencing)



#### PROBLEM#1: Diverse Expertise

- SOLUTION: funding to emphasize collaboration
- Preliminary grants to bring complementary groups together and demonstrate that they can successfully work together
- Fund cooperative grants with multi-pronged approach
  - Clinician Patient recruitment
  - Geneticist/Bioinformatics Sequencing/Candidate gene analysis
  - Basic Scientists Candidate gene screening/Mechanism discovery
  - R01s/PPG
- Foster training of physician-scientists uniquely situated to simplify "three body problem"
- Productivity metric papers & <u>return to patients</u>



# PROBLEM#2: Hypothesis generating not hypothesis driven

- Solution: Specialized study sections/Institutes prioritize these applications.
- Patient Driven Gene Discovery -> Basic Science
- Recruit patient -> Identify Candidate Gene -> screen in model systems -> Patient Phenotype -> Investigate mechanism
- Dependent Aims/"open ended"/unlikely to lead to mechanism "risky"
- Not risky -> our group and many others
- Emphasize the impact of rare disorders
- Emphasize the impact directly on patients return of results



#### Summary

- Birth defects/rare disorders huge problem
- Rare disease common collectively
- Gene identification is efficient DNA sequencing
- Opportunity
  - Transform descriptive diagnoses to molecular understanding
  - Return of clinical/research result to patients
  - Exciting basic research avenues
- Public awareness impact
- Collaborative infrastructure
- Model organisms databases, stock centers
- Special Study sections/Institute priority



#### Acknowledgments

#### Yale NewHaven Health Yale New Haven

Yale New Haven Hospital

Rick D'Aquila Cynthia Sparer



### Yale Medicine

Paul Taheri Kim Moriarty Andrew Golus Connie Branyan



#### Yale school of medicine

Carolyn Slayman (late) Cliff Bogue George Lister Antonio Giraldez

NIH – NHLBI/NICHD Sara and Jeffery Buell



# Rare disease is devastating to families – hope from gene discovery

Voice of the Patient – NIH October 2019

Kendra Haifley



Yale Medicine

Yale NewHaven Health Yale New Haven Hospital






#### Lung disease – in infancy

Onset of symptoms for proband and affected sib was around 1 year.

- interstitial lung disease, pulmonary hypertension
- mild motor delay
- Path report of proband: lung alveolar proteinosis, pectus excavatum, Trach, GJ tube
- Oldest sib is 9 yrs and well, mother pregnant fetus well to date
- Single family with disease with no known explanation
- Why study?





#### Variants in Exome Sequencing

| Pos.                   | Gene    |  | Vari<br>ant | Int<br>ole<br>ran<br>ce | MAF<br>ExAC<br>_All | MAF<br>ExAC<br>_NFE | C<br>A<br>D<br>D | SI<br>FT | PP<br>H | Effe<br>ct<br>scor<br>e | Fat<br>her | Mot<br>her | S1  |
|------------------------|---------|--|-------------|-------------------------|---------------------|---------------------|------------------|----------|---------|-------------------------|------------|------------|-----|
| 2:114500349_C<br>/T    | SLC35F5 | solute carrier family<br>35, member F5     | E224<br>K   | 53.12<br>%              | 0.0037              | 0.0058              | 20.6             | т        | В       | 1                       | Het        | Ref        | Ref |
| 2:114508135_<br>G/A    | SLC35F5 | solute carrier family<br>35, member F5     | T95I        | 53.12<br>%              | 0                   | 0                   | 21.1             | т        | Ρ       | 2                       | Ref        | Het        | Het |
| 3:49679930_C/<br>T     | BSN     | bassoon presynaptic cytomatrix protein     | P288<br>L   | 0.49%                   | 0.0035              | 0.0052              | 18.3<br>3        | т        | В       | 2                       | Het        | Ref        | Het |
| 3:49700582_G/<br>A     | BSN     | bassoon presynaptic cytomatrix protein     | R366<br>4Q  | 0.49%                   | 0.0029              | 0.0047              | 22.5             | D        | D       | 3                       | Ref        | Het        | Ref |
| 16:784797_6/<br>A      | NARFL   | nuclear prelamin A recognition factor-like | R172<br>X   | 91.39<br>%              | 0                   | 0                   | 36               | •        |         | stopga<br>in            | Ref        | Het        | Het |
| 16:786403_ <b>\</b> /C | NARFL   | nuclear prelamin A                         | -           | 91.39<br>%              | 0.0001              | 0                   |                  |          |         | 0                       | Het        | Ref        | Het |

Yale school of medicine



#### **Impact on families**

